George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOsirium Tech Regulatory News (OSI)

  • This share is currently suspended. It was suspended at a price of 2.20

Share Price Information for Osirium Tech (OSI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.20
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.00
OSI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Court Meeting and General Meeting

12 Oct 2023 15:09

RNS Number : 9748P
Osirium Technologies PLC
12 October 2023
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

 

FOR IMMEDIATE RELEASE

 

12 October 2023

 

RECOMMENDED CASH ACQUISITION

of

Osirium Technologies plc ("Osirium")

by

 

SailPoint Technologies UK Ltd ("Bidco")

(a wholly-owned indirect subsidiary of SailPoint Parent, L.P.)

to be effected by means of a Scheme of Arrangement under Part 26 of the Companies Act 2006

Results of Court Meeting and General Meeting

 

Expected timetable of principal events

 

On 30 August 2023, the boards of Osirium and Bidco announced that they had reached agreement on the terms of a recommended cash acquisition pursuant to which Bidco proposes to acquire the entire issued and to be issued share capital of Osirium (the "Acquisition"). The Acquisition is being implemented by means of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme").

 

Results of the Court Meeting and the General Meeting

 

Osirium and Bidco are pleased to announce that at the Court Meeting and General Meeting held earlier today in connection with the Acquisition:

 

1.

the requisite majority of Scheme Shareholders voted (either in person or by proxy) to approve the Scheme, being a majority in number of Scheme Shareholders present and voting either in person or by proxy, representing not less than 75 per cent. in value of the Scheme Shares voted by such Scheme Shareholders, at the Court Meeting held at 11.00 a.m. on 12 October 2023; and

2.

the requisite majority of Osirium Shareholders voted (either in person or by proxy) to pass the Resolution to implement the Scheme, including the amendment of the Articles, at the General Meeting held at 11.15 a.m. on 12 October 2023 (or as soon thereafter as the Court Meeting concluded).

Details of the resolutions passed are set out in the notices of the Court Meeting and the General Meeting contained in the circular in relation to the Scheme sent to Osirium Shareholders on and dated 18 September 2023 (the "Scheme Document"), which, subject to any restrictions relating to persons resident in Restricted Jurisdictions, is available on Osirium's website at www.osirium.com.

 

Capitalised terms used in this announcement shall, unless otherwise defined, have the meanings as set out in the Scheme Document. All references to times in this announcement are to London, United Kingdom times, unless otherwise stated.

 

Voting results of the Court Meeting

 

The table below sets out the results of the poll at the Court Meeting. Each Scheme Shareholder present (in person or by proxy) was entitled to one vote per Scheme Share held at the Voting Record Time.

 

Results of Court Meeting vote on the Scheme

Scheme Shares voted

Scheme Shareholders who voted2

Number of Scheme Shares voted as a % of the Scheme Shares eligible to be voted at the Court Meeting1

Number

%1

Number

%1

FOR

64,112,434

98.76

46

79.31

52.32

AGAINST

804,487

1.24

12

20.69

0.66

TOTAL

64,916,921

100.00

49

100.00

52.97

 

1 All percentages rounded to two decimal places.

 

2 The total number of Scheme Shareholders who voted includes 9 Scheme Shareholders ("Split Voters") who gave instructions for votes to be cast in favour of the resolution in respect of part of their holding and against the resolution in respect of another part of their holding. The aggregate number of Scheme Shareholders voting for and against the resolution exceeds the related total because such cases have been treated as involving both a number of votes cast in favour of the resolution and a number of votes cast against. For the purpose of the column of percentages, a denominator of 58 Scheme Shareholders has been used (including the Split Voters).

 

Voting results of the General Meeting

 

The table below sets out the results of the poll at the General Meeting. Each Osirium Shareholder present (in person or by proxy) was entitled to one vote per Osirium Share held at the Voting Record Time.

 

Special Resolution

Votes

FOR2

Votes

AGAINST

Total

Votes

Votes

WITHHELD

Number

%1

Number

%1

Number

Number3

To give authority to the directors to take all such action as they may consider necessary to give effect to the Scheme and amend the Company's articles of association, as set out in the Notice of General Meeting.

64,623,095

97.79

1,462,969

2.21

66,086,064

31,610

 

1 All percentages rounded to two decimal places.

 

2 Includes discretionary votes.

 

3 A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes 'For' or 'Against' the resolution.

 

The total number of Osirium Shares in issue at the Voting Record Time was 122,548,681. The Company does not hold any ordinary shares in treasury. Therefore, the total number of voting rights in Osirium at the Voting Record Time were 122,548,681.

 

Update on Conditions

 

The outcome of today's Court Meeting and General Meeting means Conditions 2.1 and 2.2 (as set out in Part A of Part III of the Scheme Document) have been satisfied.

 

Completion of the Acquisition remains subject to the satisfaction (or, where applicable, waiver) of the outstanding Conditions, which are set out in Part III of the Scheme Document.

 

Subject to the satisfaction or waiver (if capable of waiver) of the remaining Conditions, Osirium and Bidco expect that completion of the Acquisition will take place on 30 October 2023. The expected timetable of principal events relating to the Acquisition is set out in an updated format in the Appendix to this announcement.

 

Enquiries

 

SailPoint and Bidco

c/o Cavendish

 

 

Cavendish Capital Markets Limited

(Financial Adviser to SailPoint and Bidco)

Henrik Persson

Fergus Sullivan

 

+44 20 7220 0500

Osirium Technologies plc

c/o Allenby

 

 

 

Allenby Capital Limited

(Nominated Adviser, Financial Adviser and Corporate Broker to Osirium)

James Reeve/George Payne (Corporate Finance)

Tony Quirke/Stefano Aquilino (Sales and Corporate Broking)

 

+44 20 3328 5656

Alma PR (Financial PR adviser to Osirium)

Hilary Buchanan

Kieran Breheny

Will Ellis Hancock

+44 20 3405 0205

 

 

Kirkland & Ellis International LLP is acting as legal adviser to Bidco and SailPoint.

 

Blake Morgan LLP is acting as legal adviser to Osirium.

APPENDIX

 

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

 

The following dates and times associated with the Scheme are subject to change and will depend on, among other things, the date on which the Conditions to the Scheme are satisfied or, if capable of waiver, waived, and the date on which the Court sanctions the Scheme. Osirium will give adequate notice of all of these dates and times, when known, by issuing an announcement through a Regulatory Information Service, with such announcement being made available on Osirium's website at www.osirium.com. Further updates and changes to these times will be notified in the same way. See also note(1).

 

Scheme Court Hearing

26 October 2023

Last day for dealings in, and for the registration of transfer of, Osirium Shares

27 October 2023

Scheme Record Time

6:00 p.m. on 27 October 2023

Disablement of CREST in respect of Osirium Shares

6:00 p.m. on 27 October 2023

Suspension of dealings in Osirium Shares

7:30 a.m. on 30 October 2023

Effective Date of the Scheme

30 October 2023(2)

Cancellation of admission to trading of Osirium Shares

7:00 a.m. on 31 October 2023

Latest date for despatch of cheques and crediting of CREST accounts and processing electronic transfers for cash consideration due under the Scheme

13 November 2023

Long Stop Date(3)

1 March 2024

 

(1) The dates and times given are indicative only and are based on current expectations and are subject to change (including as a result of changes to the regulatory timetable).

References to times are to London, United Kingdom time unless otherwise stated. If any of the times and/or dates above change, the revised times and/or dates will be notified to Osirium Shareholders by announcement through a Regulatory Information Service.

Participants in the Osirium EMI Plan have been contacted separately to inform them of the effect of the Scheme on their rights under the Osirium EMI Plan, including details of any appropriate proposals being made and dates and times relevant to them.

(2) Bidco expects that, subject to the satisfaction (or, where applicable, waiver) of the Conditions in Part III (Conditions to the Implementation of the Scheme and to the Acquisition) of the Scheme Document, the Acquisition will become Effective on 30 October 2023.

(3) This is the latest date by which the Scheme may become Effective. However, the Long Stop Date may be extended to such later date as may be agreed by Osirium and Bidco (with the Panel's consent and as the Court may approve (if such approval(s) is/are required)).

 

Further information

 

Cavendish Capital Markets Limited ("Cavendish"), which is authorised and regulated in the United Kingdom by the FCA, is acting as financial adviser to SailPoint and Bidco and no one else in connection with the matters described in this announcement and will not be responsible to anyone other than SailPoint and Bidco for providing the protections offered to clients of Cavendish or for providing advice in connection with any matter referred to in this announcement. Neither Cavendish nor any of its affiliates (nor their respective directors, officers, employees or agents) owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Cavendish in connection with this announcement, any statement contained herein, the Offer or otherwise. No representation or warranty, express or implied, is made by Cavendish as to the contents of this announcement.

 

Allenby Capital Limited ("Allenby"), which is authorised and regulated in the United Kingdom by the FCA, is acting exclusively for Osirium and for no one else in connection with matters set out in this announcement. Allenby will not regard any other person as its client in relation to the matters referred to in this announcement and will not be responsible to anyone other than Osirium for providing the protections afforded to clients of Allenby, or for providing advice in relation to the Acquisition, the contents of this announcement or any other matters referred to in this announcement. Neither Allenby nor any of its affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Allenby in connection with the matters referred to in this announcement, or otherwise. No representation or warranty, express or implied, is made by Allenby as to the contents of this announcement.

 

This announcement is for information purposes only and is not intended to, and does not, constitute, or form part of, an offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the Acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities of Osirium in any jurisdiction in contravention of applicable law. The Acquisition will be implemented solely pursuant to the terms of the Scheme Document (or, if the Acquisition is implemented by way of an Offer, the offer document), which will contain the full terms and conditions of the Acquisition, including details of how to vote in respect of the Acquisition. Any vote in respect of the Scheme or other response in relation to the Acquisition should be made only on the basis of the information contained in the Scheme Document (or, if the Acquisition is implemented by way of an Offer, the offer document).

 

This announcement does not constitute a prospectus, prospectus equivalent document or exempted document.

 

If you are in any doubt about the contents of this announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under the Financial Services and Markets Act 2000 (as amended) if you are resident in the United Kingdom or, if not, from another appropriately authorised independent financial adviser.

 

Overseas Shareholders

 

The release, publication or distribution of this announcement in or into jurisdictions other than the UK may be restricted by law and therefore any persons who are subject to the law of any jurisdiction other than the UK should inform themselves of, and observe, any applicable legal or regulatory requirements. Any failure to comply with such requirements may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, the companies and persons involved in the Acquisition disclaim any responsibility or liability for the violation of such restrictions by any person. This announcement has been prepared in accordance with and for the purpose of complying with English law, the Takeover Code, the AIM Rules, the Market Abuse Regulation and the Disclosure Guidance and Transparency Rules and information disclosed may not be the same as that which would have been prepared in accordance with the laws of jurisdictions outside England.

 

The availability of the Acquisition to Osirium Shareholders who are not resident in and citizens of the UK may be affected by the laws of the relevant jurisdictions in which they are located or of which they are citizens. Persons who are not resident in the UK should inform themselves of, and observe, any applicable legal or regulatory requirements of their jurisdictions. In particular, the ability of persons who are not resident in the United Kingdom to vote their Osirium Shares with respect to the Scheme at the Court Meeting, or to appoint another person as proxy to vote at the Court Meeting on their behalf, may be affected by the laws of the relevant jurisdictions in which they are located. Any failure to comply with the applicable restrictions may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, the companies and persons involved in the Acquisition disclaim any responsibility or liability for the violation of such restrictions by any person. Further details in relation to Overseas Shareholders will be contained in the Scheme Document.

 

Unless otherwise determined by Bidco or required by the Takeover Code, and permitted by applicable law and regulation, the Acquisition will not be made available, directly or indirectly, in, into, from, or by the use of mails or any means or instrumentality (including, but not limited to, facsimile, e-mail or other electronic transmission, telex or telephone) of interstate or foreign commerce of, or of any facility of a national, state or other securities exchange of, any Restricted Jurisdiction where to do so would violate the laws in that jurisdiction and no person may vote in favour of the Scheme by any such use, means, instrumentality or from within a Restricted Jurisdiction or any other jurisdiction if to do so would constitute a violation of the laws of that jurisdiction. Copies of this announcement and any formal documentation relating to the Acquisition are not being, and must not be, directly or indirectly, mailed or otherwise forwarded, distributed or sent in or into or from any Restricted Jurisdiction and persons receiving such documents (including, without limitation, agents, custodians, nominees and trustees) must not mail or otherwise forward, distribute or send it in or into or from any Restricted Jurisdiction. Doing so may render invalid any related purported vote in respect of the Acquisition. If the Acquisition is implemented by way of an Offer (unless otherwise permitted by applicable law and regulation), the Offer may not be made directly or indirectly, in, into, from, or by the use of mails or any means or instrumentality (including, but not limited to, facsimile, e-mail or other electronic transmission, telex or telephone) of interstate or foreign commerce of, or of any facility of a national, state or other securities exchange of, any Restricted Jurisdiction and the Offer may not be capable of acceptance by any such use, means, instrumentality or facilities.

 

Further details in relation to overseas shareholders will be included in the Scheme Document.

 

Notice to U.S. Osirium Shareholders

 

The Acquisition relates to the shares of an English company and is being made by means of a scheme of arrangement provided for under the laws of England and Wales. A transaction effected by means of a scheme of arrangement is not subject to the tender offer or proxy solicitation rules under the U.S. Securities Exchange Act of 1934 (the "U.S. Exchange Act"). Accordingly, the Acquisition is subject to the disclosure requirements and practices applicable in the UK to schemes of arrangement which differ from the disclosure requirements of the U.S. tender offer and proxy solicitation rules. The financial information included in this announcement has been prepared in accordance with generally accepted accounting principles of the United Kingdom and thus may not be comparable to financial information of U.S. companies or companies whose financial statements are prepared in accordance with generally accepted accounting principles in the United States.

 

If, in the future, Bidco exercises its right to implement the Acquisition by way of an Offer, which is to be made into the United States, such Offer will be made in compliance with the applicable U.S. laws and regulations.

 

It may be difficult for U.S. holders of Osirium Shares to enforce their rights and any claim arising out of the U.S. federal laws, since Bidco and Osirium are located in a non-U.S. jurisdiction, and some or all of their officers and directors may be residents of a non-U.S. jurisdiction. U.S. holders of Osirium Shares may not be able to sue a non-U.S. company or its officers or directors in a non-U.S. court for violations of the U.S. securities laws. Further, it may be difficult to compel a non-U.S. company and its affiliates to subject themselves to a U.S. court's judgement.

 

In accordance with normal UK practice and pursuant to Rule 14e-5(b) of the U.S. Exchange Act, SailPoint, Thoma Bravo or their nominees, or their brokers (acting as agents), may from time to time make certain purchases of, or arrangements to purchase, Osirium Shares outside of the U.S., other than pursuant to the Acquisition, until the date on which the Acquisition becomes Effective, lapses or is otherwise withdrawn. Also, in accordance with Rule 14e-5(b) of the U.S. Exchange Act, Cavendish will continue to act as an exempt principal trader in Osirium shares on the London Stock Exchange. These purchases may occur either in the open market at prevailing prices or in private transactions at negotiated prices. Any information about such purchases will be disclosed as required in the United Kingdom, will be reported to a Regulatory Information Service and will be available on the London Stock Exchange website, www.londonstockexchange.com.

 

U.S. Osirium Shareholders also should be aware that the transaction contemplated herein may have tax consequences in the U.S. and, that such consequences, if any, are not described herein. U.S. Osirium Shareholders are urged to consult with legal, tax and financial advisers in connection with making a decision regarding this transaction.

 

Forward Looking Statements

 

This announcement (including information incorporated by reference in this announcement), oral statements made regarding the Acquisition, and other information published by Bidco and Osirium contain statements which are, or may be deemed to be, "forward-looking statements". Forward-looking statements are prospective in nature and are not based on historical facts, but rather on current expectations and projections of the management of Bidco and Osirium about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements.

 

The forward-looking statements contained in this announcement include statements relating to the expected effects of the Acquisition on Bidco and Osirium (including their future prospects, developments and strategies), the expected timing and scope of the Acquisition and other statements other than historical facts. Often, but not always, forward-looking statements can be identified by the use of forward-looking words such as "prepares", "plans", "expects" or "does not expect", "is expected", "is subject to", "budget", "projects", "synergy", "strategy", "scheduled", "goal", "estimates", "forecasts", "cost-saving", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward looking statements may include statements relating to the following: (i) future capital expenditures, expenses, revenues, earnings, synergies, economic performance, indebtedness, financial condition, dividend policy, losses and future prospects; (ii) business and management strategies and the expansion and growth of Bidco's, Osirium's, any member of the SailPoint Group's or any member of the Osirium Group's operations and potential synergies resulting from the Acquisition; and (iii) the effects of global economic conditions and governmental regulation on Bidco's, Osirium's, any member of the SailPoint Group's or any member of the Osirium Group's business.

 

Although Bidco and Osirium believe that the expectations reflected in such forward-looking statements are reasonable, Bidco and Osirium can give no assurance that such expectations will prove to be correct. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements.

 

These factors include, but are not limited to: the ability to complete the Acquisition; the ability to obtain requisite regulatory and shareholder approvals and the satisfaction of other Conditions on the proposed terms and schedule; changes in the global political, economic, business and competitive environments and in market and regulatory forces; changes in future exchange and interest rates; changes in tax rates; future business combinations or disposals; changes in general economic and business conditions; changes in the behaviour of other market participants; changes in the anticipated benefits from the proposed transaction not being realised as a result of changes in general economic and market conditions in the countries in which Bidco and Osirium operate, weak, volatile or illiquid capital and/or credit markets, changes in tax rates, interest rate and currency value fluctuations, the degree of competition in the geographic and business areas in which Bidco and Osirium operate and changes in laws or in supervisory expectations or requirements. Other unknown or unpredictable factors could cause actual results to differ materially from those expected, estimated or projected in the forward-looking statements. If any one or more of these risks or uncertainties materialises or if any one or more of the assumptions proves incorrect, actual results may differ materially from those expected, estimated or projected. Such forward-looking statements should therefore be construed in the light of such factors. Neither Bidco nor Osirium, nor any of their respective associates or directors, officers or advisers, provides any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur. You are cautioned not to place any reliance on these forward-looking statements.

 

Specifically, statements of estimated cost savings and synergies related to future actions and circumstances which, by their nature, involve risks, uncertainties and contingencies. As a result, the cost savings and synergies referred to may not be achieved, may be achieved later or sooner than estimated, or those achieved could be materially different from those estimated. Due to the scale of the Osirium Group, there may be additional changes to the Osirium Group's operations. As a result, and given the fact that the changes relate to the future, the resulting cost synergies may be materially greater or less than those estimated.

 

Other than in accordance with their legal or regulatory obligations, neither Bidco nor Osirium is under any obligation, and Bidco and Osirium expressly disclaim any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Dealing and Opening Position Disclosure Requirements

 

Under Rule 8.3(a) of the Takeover Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) of the Takeover Code applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

 

Under Rule 8.3(b) of the Takeover Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

 

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

 

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

 

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

 

Publication on a website

 

In accordance with Rule 26.1 of the Takeover Code, a copy of this announcement will be made available, subject to certain restrictions relating to persons resident in Restricted Jurisdictions, on Osirium's website at www.osirium.com by no later than 12 noon (London time) on the Business Day following this announcement. For the avoidance of doubt, neither the content of this website nor of any website accessible from hyperlinks set out in this announcement is incorporated by reference or forms part of this announcement.

 

No profit forecasts, estimates or quantified benefits statements

 

No statement in this announcement is intended as a profit forecast, profit estimate or quantified benefits statement for any period and no statement in this announcement should be interpreted to mean that earnings or earnings per share for Osirium for the current or future financial years would necessarily match or exceed the historical published earnings or earnings per share for Osirium.

 

Requesting hard copy documents

 

In accordance with Rule 30.3 of the Takeover Code, Osirium Shareholders, persons with information rights, participants in the Osirium EMI Plan and Osirium Convertible Loan Noteholders may request a hard copy of this announcement, free of charge, by contacting Allenby on +44 (0) 20 3328 5656. For persons who receive a copy of this announcement in electronic form or via a website notification, a hard copy of this announcement will not be sent unless so requested. In accordance with Rule 30.3 of the Takeover Code, such persons may also request that all future documents, announcements and information to be sent to them in relation to the Acquisition should be in hard copy form.

 

Electronic Communications

 

Please be aware that addresses, electronic addresses and certain other information provided by Osirium Shareholders, persons with information rights and other relevant persons for the receipt of communications from Osirium may be provided to Bidco during the offer period as required under Section 4 of Appendix 4 of the Takeover Code to comply with Rule 2.11(c) of the Takeover Code.

 

Rounding

 

Certain figures included in this announcement have been subjected to rounding adjustments. Accordingly, figures shown for the same category presented in different tables may vary slightly and figures shown as totals in certain tables may not be an arithmetic aggregation of figures that precede them.

 

General

 

If the Acquisition is effected by way of an Offer, and such an Offer becomes or is declared unconditional in all respects and sufficient acceptances are received, Bidco intends to exercise its rights to apply the provisions of Chapter 3 of Part 28 of the 2006 Act so as to acquire compulsorily the remaining Osirium Shares in respect of which the Offer has not been accepted.

 

Investors should be aware that Bidco may purchase Osirium Shares otherwise than under any Offer or the Scheme, including pursuant to privately negotiated purchases.

 

Disclaimer

 

The information contained herein does not constitute an offer to sell, nor a solicitation of an offer to buy, any security, and may not be used or relied upon in connection with any offer or solicitation. Any offer or solicitation in respect of SailPoint will be made only through a confidential private placement memorandum and related documents which will be furnished to qualified investors on a confidential basis in accordance with applicable laws and regulations. The information contained herein is not for publication or distribution to persons in the U.S. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold without registration thereunder or pursuant to an available exemption therefrom. Any offering of securities to be made in the U.S. would have to be made by means of an offering document that would be obtainable from the issuer or its agents and would contain detailed information about the issuer of the securities and its management, as well as financial information. The securities may not be offered or sold in the U.S. absent registration or an exemption from registration.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMFLFISIDLFLIV
Date   Source Headline
31st Oct 20237:00 amRNSCancellation - Osirium Technologies plc
30th Oct 202310:39 amRNSSCHEME OF ARRANGEMENT BECOMES EFFECTIVE
30th Oct 20237:30 amRNSSuspension - Osirium Technologies plc
26th Oct 202311:22 amRNSCourt Sanction of Scheme of Arrangement
12th Oct 20233:09 pmRNSResults of Court Meeting and General Meeting
28th Sep 20234:33 pmRNSForm 8.3 - Osirium Technologies plc
27th Sep 20231:36 pmRNSForm 8.3 - Osirium Technologies plc
18th Sep 20237:00 amRNSPublication and Posting of Scheme Document
14th Sep 20231:34 pmRNSForm 8.3 - Osirium Technologies PLC
8th Sep 20232:08 pmRNSForm 8.3 - Osirium Technologies plc
7th Sep 20234:09 pmRNSForm 8.3 - Osirium Technologies plc
7th Sep 20237:00 amRNSInterim Results
5th Sep 20233:14 pmGNWCorrection: Form 8.3 - Octopus Investments - Osirium Technologies plc
5th Sep 20237:00 amRNSForm 8 (OPD) Osirium Technologies plc
1st Sep 20234:58 pmRNSForm 8.3 - Osirium Technologies plc
1st Sep 202311:10 amRNSForm 8.3 - Osirium Technologies plc- Amendment
31st Aug 20234:24 pmRNSForm 8.3 - Osirium Technologies PLC
31st Aug 20232:02 pmGNWForm 8.3 - Osirium Technologies plc
31st Aug 202311:28 amRNSForm 8.3 - Osirium Technologies plc
31st Aug 202310:51 amRNSForm 8.3 - Osirium Technologies plc
31st Aug 20239:50 amRNSForm 8 (DD) - Osirium Technologies plc
30th Aug 202312:00 pmRNSRecommended Acquisition of Osirium Technologies
18th Jul 20237:00 amRNSHalf Year Trading Update
13th Jun 20237:00 amRNSAttendance at InfoSec Europe 2023
22nd May 20237:00 amRNSGrant of Options and PDMR Dealings
9th May 202312:40 pmRNSResult of AGM
9th May 20237:00 amRNSAGM Statement and Q1 trading update
18th Apr 20237:00 amRNSUpdate re proposed grant of options
3rd Apr 20237:00 amRNSNotice of AGM & Proposed Changes to Option Scheme
24th Mar 20234:40 pmRNSSecond Price Monitoring Extn
24th Mar 20234:35 pmRNSPrice Monitoring Extension
23rd Mar 20237:00 amRNSFinal Results
10th Jan 20232:05 pmRNSSecond Price Monitoring Extn
10th Jan 20232:00 pmRNSPrice Monitoring Extension
9th Jan 20239:00 amRNSPrice Monitoring Extension
9th Jan 20237:00 amRNSFull Year Trading Update
4th Jan 202311:59 amRNSHolding(s) in Company
3rd Jan 20237:00 amRNSConfirmation of Board Changes
30th Dec 20227:00 amRNSTotal Voting Rights
19th Dec 202210:30 amRNSHoldings in Company
15th Dec 202211:51 amRNSHolding(s) in Company
15th Dec 20227:00 amRNSHolding(s) in Company
14th Dec 20222:25 pmRNSHolding(s) in Company
12th Dec 202210:19 amRNSResult of General Meeting
30th Nov 20227:00 amRNSTotal Voting Rights
28th Nov 20223:12 pmRNSTR-1: Notification of Major Holdings
28th Nov 20223:11 pmRNSTR-1: Notification of Major Holdings
28th Nov 20223:10 pmRNSTR-1: Notification of Major Holdings
22nd Nov 20227:00 amRNSProposed Placing, Subscription, Board Changes & GM
1st Nov 202211:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.